Clinical Trial Update: An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) [Phase 2]

View source ↗

Summary

Phase 2 open-label study assessing defibrotide for the prevention of acute graft-versus-host disease completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Defibrotide (defibrotide)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Graft-versus-host Disease, Acute-graft-versus-host Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-08-18